Recent reports also reveal that CD8+ T cells can be activated by MHC I–negative tumor cells through NKG2D engagement after prior antigen-specific activation by MHC I–positive tumor cells or adjacent myeloid antigen-presenting cells (5). This evidence concerns the gene CD8A and neoplasm.